Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Feasibility of Identifying High-Risk Glaucoma Patients Before the Onset of Disease
Author Affiliations & Notes
  • Mohammad Eslami
    Harvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Saber Kazeminasab Hashemabad
    Harvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Hannah Rana
    Harvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Milen Raytchev
    Harvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Yan Luo
    Harvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Min Shi
    Harvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Yu Tian
    Harvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Michael G. Morley
    Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Nazlee Zebardast
    Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Michael V. Boland
    Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • David S Friedman
    Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Mengyu Wang
    Harvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Tobias Elze
    Harvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Mohammad Eslami None; Saber Kazeminasab Hashemabad None; Hannah Rana None; Milen Raytchev None; Yan Luo None; Min Shi None; Yu Tian None; Michael Morley None; Nazlee Zebardast None; Michael Boland None; David Friedman None; Mengyu Wang Genentech Inc, Code F (Financial Support); Tobias Elze Genentech Inc, Code F (Financial Support)
  • Footnotes
    Support  NIH R01 EY030575, NIH P30 EY003790, NIH K23 5K23EY032634, NIH R21 5R21EY032953, NIH R21 EY035298, NIH R00 EY028631, Research to Prevent Blindness International Research Collaborators Award, Research to Prevent Blindness Career Development Award
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 1621. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mohammad Eslami, Saber Kazeminasab Hashemabad, Hannah Rana, Milen Raytchev, Yan Luo, Min Shi, Yu Tian, Michael G. Morley, Nazlee Zebardast, Michael V. Boland, David S Friedman, Mengyu Wang, Tobias Elze; Feasibility of Identifying High-Risk Glaucoma Patients Before the Onset of Disease. Invest. Ophthalmol. Vis. Sci. 2024;65(7):1621.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : This study investigates the potential for identifying high-risk glaucoma patients despite the presence of normal mean deviations (MD) on visual field (VF) tests, presenting a challenging prognosis scenario.

Methods : Our study retrospectively analyzed SITA Standard 24-2 visual field data from patients at the Mass. Eye and Ear glaucoma service. To be included, patients required at least three visits with reliable tests and normal GHT and MD values (-2.1 to +2.1dB) in their first two visits. Patients with subsequent GHT values that fell outside the normal range or became borderline were categorized as high-risk or converters. This study focuses on identifying converters using only the information from the first two visits, employing two well-known methods for tabular data: XGBoost and TabNet, a deep learning technique. The dataset was split 75/25 for training and testing, with a 20% validation sub-set. Feature importance analyses were performed on both the training set (using built-in methods) and the test set (using permutation importance) to identify the most influential features. As shown in Figure 2A, the predictive features from the baseline and 2nd visits are race, values of age, MD, PSD and archetypes decomposition coefficients of baseline total deviations (TDs) and their changes. Archetype analysis was employed to identify potential representative patterns within the baseline TDs (8 archetypes) and their changes (2nd visit-1st visit, 11 archetypes).

Results : A total of 6,686 eyes from 5,467 patients met our study criteria, of which 1,874 eyes were identified as converters. Figure 1 illustrates the characteristics of the data. Using all features, converter identification performance (F1-score TabNet 65% vs. XGBoost 64%, Fisher's exact p-value <0.05 (Figure 2A)), demonstrates the potential for identification despite the inherent challenges. However, significant discrepancies in the feature importance rankings were observed between methods, as depicted in Figures 2B to 2E. This highlights the complexity of the task and the need for further investigation to identify the most crucial factors for converter prediction.

Conclusions : Our study shows potential for early identification of high-risk glaucoma patients, but further research to improve accuracy (e.g., by incorporating genetics, retina images, and IOP measurements/events), investigate uncertainty, and address variations in feature importance is needed.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×